Skip to main content
Equibles
BOLD logo

BOLD · Boundless Bio, Inc.

Track BOLD — free

Use BOLD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BOLD

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.83 +0.06 (+1.98%) At close · Aug 14
Market Cap
$64.38M
Shares
22.75M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.83 Open$2.78 Day$2.74–2.84 52W close$1.05–2.89 Avg vol 30d249K Short int224K · 1.0% float · 1.5d Short vol43% DataMar 2024–Aug 2026 Filing10-Q · Aug 7

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 7, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +87%
above
Price vs 50-day avg +24%
above
RSI (14) 69
neutral
MACD trend Negative
52-week position 97%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +14%
trailing
6-month return +146%
trailing
YTD return +136%
this year
Relative strength +132%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +14 funds added
Insider flow Accumulating
Net +$1.4M over 90 days · 67% sells
Short interest Falling
0.98% of float · ▼ -6.9% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
40 holders — mid 2-yr range
Squeeze score 51
elevated · 0–100
Fundamentals
Strong
EPS growth +32%
Y/Y
Free cash flow $-47.2M
Balance sheet $17.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 100%
annualized · 1-yr
Max drawdown −30%
past year
ATR 4.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+87% Bullish
Price vs 50-day avg
+24% Bullish
RSI (14)
69 Neutral
MACD trend
Negative Bearish
52-week position
97% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +14 funds added
Insider flow Accumulating
Net +$1.4M over 90 days · 67% sells
Short interest Falling
0.98% of float · ▼ -6.9% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
40 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $1 Now $3 · 97% Range high $3
vs 200-day avg +87% vs 50-day avg +24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and short-term investments $92.8M first quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BOLD
Boundless Bio, Inc.
this stock
$64.38M +135.8% — — 1.0%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
40
% held
67.2%
Net QoQ
+6.8M sh
Top holder
ARCH Venture Management,…
Held Float
View
Held by Funds
Fund positions
11
View
Short & Settlement
Short Interest Falling
Shares short
223.8K
Days to cover
1.5d
Change
-16.6K sh
View
Short Volume
Short vol %
43%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
3.6K
Value
$8.9K
As of
Jun 30, 2026
View
Off-Exchange
Off-exchange %
39.8%
Week of
Jul 6, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$1.4M
Buyers / Sellers
1 / 2
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-58.2M
EPS diluted
$-2.60
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 7, 2026
This year
10
View
Exempt Offerings
Offering
$100.0M
Filed
Aug 15, 2023
View
Earnings & Events
Earnings Calls
Last call
Jun 23, 2026
View

Performance

5D 20D 120D MTD YTD
BOLD -2.1% +14.1% +146.1% +13.2% +135.8%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -2.5% +9.7% +132.3% +9.3% +122.0%
Key facts CIK 1782303 CUSIP 10170A100 13F (30d) 41 filings 39 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)